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Although trefoil factor 1 (TFF1; previously named pS2) is
abnormally expressed in about 50% of human breast
tumors, its physiopathological role in this disease has been
poorly studied. Moreover, controversial data have been
reported. TFF1 function in the mammary gland therefore
needs to be clariﬁed. In this study, using retroviral vectors,
we performed TFF1 gain- or loss-of-function experiments
in four human mammary epithelial cell lines: normal
immortalized TFF1-negative MCF10A, malignant TFF1-
negative MDA-MB-231 and malignant TFF1-positive
MCF7 and ZR75.1. The expression of TFF1 stimulated
the migration and invasion in the four cell lines. Forced
TFF1 expression in MCF10A, MDA-MB-231 and MCF7
cells did not modify anchorage-dependent or -independent
cell proliferation. By contrast, TFF1 knockdown in
MCF7 enhanced soft-agar colony formation. This in-
creased oncogenic potential of MCF7 cells in the absence
of TFF1 was conﬁrmed in vivo in nude mice. Moreover,
chemically induced tumorigenesis in TFF1-deﬁcient
(TFF1-KO) mice led to higher tumor incidence in the
mammary gland and larger tumor size compared with
wild-type mice. Similarly, tumor development was in-
creased in the TFF1-KO ovary and lung. Collectively, our
results clearly show that TFF1 does not exhibit oncogenic
properties, but rather reduces tumor development. This
beneﬁcial function of TFF1 is in agreement with many
clinical studies reporting a better outcome for patients
with TFF1-positive breast primary tumors.
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Introduction
Trefoil factor 1 (TFF1; previously named pS2) (HUGO
Gene Nomenclature Committee; http://www.genenames.
org) is a small cysteine-rich acidic secreted protein
(Thim, 1997; Ribieras et al., 1998). It is constitutively
and strongly expressed in the stomach, where it has a
key role (Rio et al., 1988). Indeed, TFF1 is essential
for the normal differentiation of the gastric glands
(Bossenmeyer-Pourie et al., 2002; Karam et al., 2008).
Moreover, by interacting with mucins, TFF1 partici-
pates in the correct organization of the mucus layer and
in the gastric mucosa protection (Tomasetto et al.,
2000). Transgenic mice overexpressing TFF1 have an
increased resistance to ulceration (Playford et al., 1996).
TFF1 is also expressed in the inﬂamed or damaged
gastrointestinal tract, supporting the hypothesis that it
mediates repair processes (Rio et al., 1991; Kjellev,
2009). Indeed, TFF1 promotes epithelial restitution
after injury and protects the integrity of the epithelial
barrier (Hoffmann, 2005). Moreover, TFF1 is also
expressed, but to a lesser extent, by normal epithelial
cells of numerous organs (eyes, lung, ovary and salivary
gland) (Regalo et al., 2005; Madsen et al., 2007; Buron
et al., 2008). To date, the TFF1 function during
malignant processes is not clearly deﬁned, as epithelial
cell transformation might lead to downregulation of
TFF1 expression (that is, in the stomach) or to the
induction of TFF1 expression (that is, in various
organs).
In the stomach, TFF1-deﬁcient mice (TFF1-KO)
develop antro-pyloric hyperplasia and dysplasia, leading
to adenomas and intraepithelial or intramucosal carci-
nomas (Lefebvre et al., 1996). Epithelial progenitors are
ampliﬁed and are more invasive (Karam et al., 2008). It
has therefore been proposed that TFF1 functions as a
gastric tumor suppressor gene. Strongly supporting this
hypothesis, 50% of human gastric tumors are devoid of
TFF1 because of deletions, mutations or methylation of
the TFF1 gene (Ribieras et al., 1998; Katoh, 2003; Shi
et al., 2006).
Breast cancer is a typical example of cancers over-
expressing TFF1. As only a low expression is observed
in the normal mammary gland (Poulsom et al., 1997;
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suggested that, in breast cancers, high levels of TFF1
may have a pejorative function and that TFF1 should
even be regarded as an oncogene (Perry et al., 2008).
Supporting this hypothesis, in kidney and colon cancer
cells overexpressing TFF1, TFF1 activates signaling
pathways involved in cell survival, anchorage-indepen-
dent growth, invasion and/or angiogenesis processes
(Emami et al., 2001; Rodrigues et al., 2003, 2006).
Furthermore, TFF1 has been associated with breast
cancer bone metastases (Smid et al., 2006). However,
contrary to this view, numerous data have also
suggested a beneﬁcial role of TFF1 expression in human
breast cancers. TFF1 is a classical estrogen-regulated
gene possessing a canonical estrogen response element
on its promoter (Ribieras et al., 1998). Consequently,
TFF1 is expressed in about 50% of breast primary
tumors, most of them estrogen receptor (ER) positive, a
tumor subclass of better prognosis (Dunnwald et al.,
2007). TFF1 is also expressed in metastases derived
from TFF1-positive primary tumors (Rio et al., 1987). It
is an informative marker for the detection of micro-
metastases (Mikhitarian et al., 2005). Moreover,
patients with ER
þ/TFF1
þ primary tumors have a better
prognosis than patients with ER
þ/TFF1
  tumors (Rio
et al., 1987; Foekens et al., 1990), and TFF1 constitutes
a potent marker of hormone-dependent breast tumors
and of hormone-therapy responsiveness (Ribieras et al.,
1998; Chenard et al., 2004). Finally, transgenic mice
expressing TFF1 in their mammary glands do not
show increased cell proliferation or tumor formation
(Tomasetto et al., 1989). Thus, despite numerous
studies, TFF1 physiopathological function in breast
cancers remains controversial.
To further address this question, we performed TFF1
loss- and gain-of-function approaches using normal
(immortalized), ER-positive and ER-negative malignant
human mammary cell lines, and tumorigenesis experi-
ments in nude mice and TFF1-KO mice. Collectively,
our results favor a beneﬁcial function of TFF1 during
malignant processes in breast cancers.
Results
Generation of MCF10A normal breast cells, and
MDA-MB-231 and MCF7 breast cancer cells
constitutively expressing TFF1
To test the oncogenic properties of TFF1, the human
immortalized normal breast cell line MCF10A and ER-
negative breast cancer cell line MDA-MB-231, which do
not express TFF1 (deFazio et al., 2000; Mackay et al.,
2009), were stably modiﬁed using pQCXIP retroviral
vectors containing or not hTFF1 complementary DNA
(Figure 1a). Western blot analysis of cell extracts
showed that the MCF10A/CTL (pQCXIP) control
cells do not express TFF1, whereas MCF10A/TFF1
(pQCXIP hTFF1) cells displayed strong TFF1 protein
expression. As expected, conditioned medium analysis
showed that TFF1 was secreted only by MCF10A/
TFF1 cells (Figure 1b). Similarly, strong TFF1 expres-
sion and secretion were observed in MDA-MB-231/
TFF1 (pQCXIP hTFF1) cells, whereas MDA-MB-231/
CTL (pQCXIP) control cells were devoid of TFF1
(Figure 1c). To test the effect of forced TFF1 expression
in an ER-positive breast cancer cell line, we established
MCF7/TFF1 cells. MCF7 cells are known to express
and secrete high endogenous TFF1 levels when cultured
in the presence of estrogens (E2) (Ribieras et al., 1998)
(Figure 1d, compare MCF7/CTLþ/  E2). MCF7/
TFF1 expressed high amounts of TFF1. Thus, the
pQCXIP hTFF1 retroviral vector efﬁciently induces
TFF1 expression in MCF10A, MDA-MB-231 and
MCF7 mammary cells.
pQCXIP hTFF1 expression enhances MCF10A,
MDA-MB-231 and MCF7 cell migration and invasion
To test the functionality of our TFF1 gain-of-function
cell models, we investigated the impact of TFF1 on cell
migration and invasion, as numerous studies indicate
that TFF1 favors these biological processes in normal
and malignant conditions (Ribieras et al., 1998;
Prest et al., 2002; Amiry et al., 2009). Using Transwell
membranes, we observed that the migration of
MCF10A/TFF1 cells was increased compared with
MCF10A/CTL cells (Figure 2Aa; 2.9-fold, Po0.001).
Figure 1 Induction of constitutive TFF1 expression in MCF10A,
MDA-MB-231 and MCF7 breast epithelial cells. (a) pQCXIP and
pQCXIP hTFF1 retroviral vectors. (b) Total proteins from whole-
cell lysates (Cell Extr) and conditioned medium (Cond Med) from
MCF10A/CTL and MCF10A/TFF1 cells were separated by
10–20% gradient SDS–polyacrylamide gel electrophoresis and
subjected to TFF1 immunoblot analysis using the p28O2 antibody.
MCF10A/TFF1 cells strongly expressed and secreted TFF1,
whereas MCF10A/CTL cells were completely TFF1 negative.
(c) Western blot showed that MDA-MB-231/TFF1 cells expressed
and secreted TFF1, whereas MDA-MB-231/CTL cells remained
TFF1 negative. (d) Western blot analysis of MCF7/CTL and
MCF7/TFF1 cells shows that TFF1 is overexpressed regardless of
E2 status. Note that, in the presence of E2, endogenous TFF1 is
strongly expressed and secreted by MCF7/CTL cells. b-Actin,
tubulin and Cath-D served as loading controls.
TFF1 is not an oncogene in the mammary gland
E Buache et al
3262
OncogeneSimilarly, the motility of MDA-MB-231/TFF1 cells was
increased compared with MDA-MB-231/CTL cells
(Figure 2Ab; 1.6-fold, Po0.01). Finally, MCF7/TFF1
cell migration was increased when cells were grown in
the absence of E2 (no endogenous TFF1 expressed)
(Figure 2Ac; 1.7-fold, Po0.001). Cell invasion was
assessed using Transwell membranes coated with
Matrigel, a reconstituted basement membrane. The
invasiveness of MCF10A/TFF1 cells was increased
compared with MCF10A/CTL cells (Figure 2Ba; 1.6-
fold, Po0.001), as that of MDA-MB-231/TFF1 cells
compared with MDA-MB-231/CTL cells (Figure 2Bb;
1.3-fold, Po0.05). MCF7/TFF1 cells showed increased
invasiveness compared with MCF7/CTL, only in the
absence of E2 (Figure 2Bc; 1.8-fold, Po0.001). Thus,
TFF1 stimulates the migration and invasion in both
normal and malignant human breast epithelial cells.
Moreover, in MCF7/TFF1 cells, the impact of pQCXIP
hTFF1 was observed only in the absence of E2, indicating
that, in the presence of E2, endogenous TFF1 already has
an optimal function (Figure 2Ac and Bc).
pQCXIP hTFF1 expression does not modify MCF10A,
MDA-MB-231 and MCF7 cell proliferation or clonal cell
growth in soft agar
We then studied the cell proliferative capacity that is
dependent on TFF1 expression using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) method. Cells were grown in 1% fetal calf
serum. We observed that forced TFF1 expression had
no effect, as MCF10A/CTL and MCF10A/TFF1 cells
exhibited similar proliferative curves (Figure 3Aa), such
as MDA-MB-231/CTL and MDA-MB-231/TFF1 cells
(Figure 3Ab), and MCF7/CTL and MCF7/TFF1 cells
(Figure 3Ac). Both MCF7/CTL and MCF7/TFF1
proliferated very slowly in the absence of E2 as expected
for E2-dependent cells (Figure 3Ac). MCF10A, MDA-
MB-231 and MCF7 cells stably modiﬁed for TFF1
expression were then used to determine the possible
oncogenic function of TFF1 in vitro using a soft-agar
anchorage-independent growth test that identiﬁes trans-
formed cells (Thullberg and Stromblad, 2008). As
expected, the immortalized but not transformed
MCF10A/CTL cells did not form colonies. No colonies
were observed with MCF10A/TFF1 cells, demonstrat-
ing that TFF1 expression is not sufﬁcient to transform
MCF10A cells (Figure 3Ba). Moreover, MDA-MB-231/
CTL and MDA-MB-231/TFF1 cancer cells developed
similar colony number (Figure 3Bb). Neither MCF7/
CTL nor MCF7/TFF1 developed colonies in the
absence of E2, and similar colony numbers were
observed in the presence of E2 (Figure 3Bc). Thus,
forced TFF1 expression does not induce cell prolifera-
tion or improve the in vitro oncogenic properties in
normal or malignant mammary epithelial cells.
pQCXIP hTFF1 expression does not modify in vivo
tumorigenesis in the MCF7 xenograft model
To check the in vivo effect of forced TFF1, MCF7/CTL
or MCF7/TFF1 cells were injected subcutaneously into
nude mice in the absence or presence of E2. E2 was
added in the drinking water (Mira et al., 2004). We
studied the kinetics of tumor occurrence and tumor
volume. In the absence of E2, no tumors developed. In
the presence of E2, tumors developed but no statistical
differences were observed between the cell lines
(Figure 4a). At the end of the experiment, 75% of
MCF7/TFF1 and 85.7% of MCF7/CTL mice presented
tumors. Moreover, tumor growth rates were similar
regardless of their TFF1 status (Supplementary Figure
S1A). Western blot (Figure 4b) and immunohistochem-
ical analyses (Figure 4c) of the tumors conﬁrmed high
TFF1 expression levels in both MCF7/CTL (endogen-
ous TFF1 expression) and MCF7/TFF1 (endogenous
TFF1 plus pQCXIP-induced TFF1 expression) cells.
Thus, in agreement with the in vitro soft-agar data,
MCF7 tumorigenicity is not signiﬁcantly modiﬁed
in vivo, subsequent to pQCXIP hTFF1 expression.
Generation of MCF7 and ZR75.1 breast cancer cells
knocked down for endogenous TFF1 expression
The second part of our study concerns TFF1 loss-of-
function. This was achieved by downregulating endo-
genous TFF1, using shRNA strategy. Although TFF1
messenger RNA is a short messenger RNA, analysis
allowed us to design ﬁve potential TFF1-speciﬁc shRNA
sequences scattered along TFF1 messenger RNA (21
nucleotides each) (Figure 5a). MCF7 cells were stably
modiﬁed using pLMP retroviral vectors expressing these
shTFF1s or scramble shRNA (pLMP shTFF1#1–5 and
pLMP shScr, respectively; Figure 5b). As endogenous
TFF1 was not expressed in the absence of E2 in MCF7
cells (Ribieras et al., 1998) (Figure 1d), all experiments
were performed in the presence of E2. As expected,
MCF7/shScr expressed high TFF1 levels, whereas
MCF7/shTFF1#1–5 exhibited from 50% to more than
90% decrease in TFF1 expression and secretion, as
shown by western blot analysis of cell extract and
conditioned culture media (Figure 5c). shTFF1#1 and
shTFF1#4 were the two most efﬁcient and were chosen
for further experiments. A second ER-positive cell line,
ZR75.1, was similarly modiﬁed using pLMP shTFF1#1,
pLMP shTFF1#4 and pLMP shScr vectors. Similar to
MCF7 cells, both ZR75.1/shTFF1#1 and ZR75.1/
shTFF1#4 exhibited dramatic decrease in TFF1 expres-
sion and secretion (Figure 5d). Thus, the pLMP
shTFF1#1 and pLMP shTFF1#4 retroviral vectors
efﬁciently knock down TFF1 expression in MCF7 and
ZR75.1 cells.
Endogenous TFF1 knockdown reduces MCF7 and
ZR75.1 cell migration and invasion
We investigated the impact of TFF1 knockdown in
MCF7 and ZR75.1 cells on cell migration and invasion.
Using Transwell membranes, we observed that the
migration of MCF7/shTFF1#1 and MCF7/shTFF1#4
cells displayed a decrease in migration compared with
MCF7/shScr cells (Figure 6Aa; twofold and threefold,
respectively, Po0.001). Similarly, the motility of
ZR75.1/shTFF1#1 and ZR75.1/shTFF1#4 cells showed
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(Figure 6Ab; twofold, Po0.001). Moreover, cell
invasion through Matrigel-coated Transwell membranes
of MCF7/shTFF1#1 and MCF7/shTFF1#4 cells
were decreased compared with MCF7/shScr cells
(Figure 6Ba; 1.8-fold, Po0.001 and 1.5-fold, Po0.01,
respectively). Similarly, ZR75.1/shTFF1#1 and ZR75.1/
shTFF1#4 cell invasion was decreased compared with
ZR75.1/shScr cells (Figure 6Bb; 1.6-fold, Po0.001).
Thus, knockdown of endogenous TFF1 lowers migra-
Figure 2 Impact of constitutive TFF1 on MCF10A, MDA-MB-231 and MCF7 cell migration and invasion. (A) Crystal violet-stained
migrated cells present at the lower face of the Transwell membranes were counted with an inverted microscope; (a) increased MCF10A/
TFF1 migration compared with MCF10A/CTL (Po0.001); (b) similar results for MDA-MB-231/TFF1 versus MDA-MB-231/CTL
cells (Po0.01); (c) similar results for MCF7/TFF1 versus MCF7/CTL cells (Po0.001); no effect was shown for MCF7/TFF1 cells in
the presence of E2. (B) Invasive cells through matrigel-coated membranes were analyzed as in A. TFF1 expression increases invasion,
regardless of the cell tested (a and c, Po0.001; b, Po0.05). No effect was shown for MCF7/TFF1 cells in the presence of E2.
Histograms: mean±s.e. of triplicates. NS, not signiﬁcant.
Figure 3 Impact of constitutive TFF1 on MCF10A, MDA-MB-231 and MCF7 cell proliferation and colony formation in soft agar.
(A) cell proliferation: MCF10A/CTL and MCF10A/TFF1 (a), MDA-MB-231/CTL and MDA-MB-231/TFF1 (b) and MCF7/CTL
and MCF7/TFF1 cells (c) were cultured for 5 days in culture medium containing 1% fetal calf serum, and counted using the MTT
method. No signiﬁcant differences (NS) were observed regardless of TFF1 status. Note that MCF7/TFF1 and MCF7/CTL cell
proliferation were low in the absence of E2. (B) Cells were agar embedded. After 18 days, colonies were stained (crystal violet) and
counted. (a) MCF10A/TFF1 and MCF10A/CTL did not form colonies. (b) MDA-MB-231/TFF1 and MDA-MB-231/CTL cells gave
rise to colonies of similar number (NS). (c) In the absence of E2, MCF7/TFF1 and MCF7/CTL colony numbers were very low.
However, in the presence of E2 (10nM), the number of colonies increased in both MCF7/TFF1 and MCF7/CTL in a similar manner
(NS). Histograms: mean±s.e. of triplicates.
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conﬁrming that TFF1 has a key role in these processes.
Endogenous TFF1 knockdown does not modify MCF7
and ZR75.1 cell proliferation, but increases the clonal
growth of MCF7 cells in soft agar
TFF1 knockdown did not modify cell proliferation
capacity, as no differences were observed between the
proliferative curves of MCF7/shScr, MCF7/shTFF1#1
and MCF7/shTFF1#4 cells (Figure 7a). Similar data were
obtained using the ZR75.1 cells (data not shown). We
then tested the impact of TFF1 knockdown on MCF7/
shTFF1#1 and MCF7/shTFF1#4 soft-agar anchorage-
independent growth. We observed increased colony
numbers compared with MCF7/shScr (Figure 7b;
Po0.001 and Po0.01, respectively). Thus, TFF1 knock-
down does not modify cell proliferation but increases
in vitro oncogenicity of ER-positive breast cancer cells.
Endogenous TFF1 knockdown in MCF7 cells improves
tumor formation in nude mice
To check the in vivo effect of TFF1 loss-of-function,
pools of MCF7/shScr or MCF7/shTFF1#1 cells were
injected subcutaneously into nude mice (two sets of 12
mice each). E2 was added in the drinking water (Mira
et al., 2004). The delay for the ﬁrst tumor occurrence
was higher for MCF7/shScr than for MCF7/shTFF1#1
tumors (12 versus 26 days after injection) (Figure 8a).
Moreover, 50% of the injected mice developed MCF7/
shTFF1#1 tumors after 28 days, whereas 47 days were
necessary for MCF7/shScr tumors to reach the same
incidence (Po0.01). Finally, 60 days after injection,
90% of the mice injected with MCF7/shTFF1#1 cells
exhibited tumors versus 55% for MCF7/shScr cells. This
remained true for 124 days after injection. However,
once detected, tumor growth rates were similar regard-
less of their TFF1 status (Supplementary Figure S1B).
Tumor immunohistochemical analysis conﬁrmed very
low TFF1 expression in MCF7/shTFF1#1 cells com-
pared with MCF7/shScr cells (Figure 8b). Thus, in
agreement with the in vitro soft-agar data, MCF7
tumorigenicity is signiﬁcantly increased in vivo, subse-
quent to TFF1 knockdown.
Endogenous TFF1 reduces DMBA-induced tumorigenesis
in mice
We then tested the impact of endogenous TFF1 on
chemically induced tumors in 12 wild-type and 12
TFF1-KO littermate females by intragastric adminis-
tration once a week during 6 weeks of 7,12-dimethyl-
benz[a]anthracene (DMBA), a procarcinogen (Lefebvre
et al., 1996; Masson et al., 1998). Twenty-two weeks
after, mice were killed, and systematic histological
examination of the liver, lung, mammary gland (all of
Figure 4 Impact of forced TFF1 expression on MCF7 cell tumorigenicity in nude mice. (a) Tumor occurrence after subcutaneous
injection in nude mice of 10
6 cells. Curves showed that MCF7/CTL and MCF7/TFF1 did not develop tumors in the absence of E2. In
the presence of E2, both cell lines developed tumors in a similar manner (NS). (b) Western blot showed that MCF7/CTL tumor cells
expressed TFF1 (endogenous TFF1), as well as MCF7/TFF1 (endogenous TFF1 plus pQCXIP TFF1). (c) Tumor immuno-
histochemistry conﬁrmed TFF1 expression (brown). Bars: 30mm.
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tumors. Table 1 recapitulates the results of one of the
two independent experiments (each including 24 mice)
that gave similar results. Two TFF1-KO mice died
before the end of the experiments. In the mammary
gland, a threefold increase in tumor incidence was
observed in TFF1-KO mice, although this was not
signiﬁcant. Nevertheless, a strong and signiﬁcant in-
crease in tumor size was observed in TFF1-KO mice
(4.4-fold; Po0.01). Moreover, all TFF1-KO mice and
50% of the wild-type mice exhibited malignant ovarian
tumors (Po0.01). Ovaries never presented more than
one tumor. The size of ovarian carcinoma was smaller in
wild-type mice (mean: 1.82 versus 3.75mm; Po0.001).
In the lung, although tumor incidence was similar, the
number of tumors per mouse was higher in the TFF1-
KO mice (mean: 3.5 versus 1.4; Po0.001). Finally, no
liver tumors were detected in all mice regardless of TFF1
status. Thus, endogenous TFF1 reduces in vivo mouse
tumor development and/or progression, not only in the
mammary gland but also in other organs, such as the
ovary and the lung.
Discussion
This study was undertaken to bring additional clues
concerning the function of TFF1 in breast carcinomas.
Indeed, its physiopathological role in this disease is not
well understood to date. We showed that TFF1
promotes cell migration and invasion in all cells tested.
Moreover, TFF1 gain-of-function experiments per-
formed in ER-negative or ER-positive mammary cells
showed that TFF1 does not exhibit in vitro and in vivo
pro-tumor properties. Conversely, TFF1 loss-of-func-
tion performed in ER-positive mammary cells showed
in vitro and in vivo anti-tumor effects for TFF1. The
lower DMBA-induced tumor development observed in
TFF1-KO mice strongly supports these results.
Figure 5 Knockdown of TFF1 expression in MCF7 and ZR75.1 breast epithelial cells. (a) TFF1 messenger RNA complete sequence;
the ATG start site and the TAG stop codon are in bold, and the coding sequence (CDS) in yellow. Putative TFF1 shRNA sequences
are underlined as indicated. (b) pLMP shScr and pLMP shTFF1 retroviral vectors. (c) Western blot analysis of cell extracts and
conditioned medium showed that endogenous TFF1 protein levels were higher in MCF7/shScr than in all MCF7/shTFF1s cells.
shTFF1#1 and shTFF1#4 were the most efﬁcient in knocking TFF1 in MCF7 cells. (d) Similarly, ZR75.1/shTFF1#1 and ZR75.1/
shTFF1#4 showed a dramatic TFF1 decrease compared with ZR75.1/shScr. Tubulin and Cath-D are loading controls.
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OncogeneFigure 6 Impact of TFF1 knockdown on MCF7 and ZR75.1 cell migration and invasion. (A) Number of crystal violet-stained
migrated cells present at the lower face of the Transwell membranes; (a) decreased MCF7/shTFF1#1 and MCF7/shTFF1#4 cell
migration compared with MCF7/shScr (Po0.001); (b) similar results for ZR75.1/shTFF1#1 and ZR75.1/shTFF1#4 compared with
ZR75.1/shScr (Po0.001). (B) Number of invasive cells through matrigel-coated membranes; (a) decreased MCF7/shTFF1#1 and
MCF7/shTFF1#4 cell invasion compared with MCF7/shScr (Po0.001 and Po0.01, respectively); (b) similar results for ZR75.1/
shTFF1#1 and ZR75.1/shTFF1#4 compared with ZR75.1/shScr (Po0.001). Histograms: mean±s.e. of triplicates.
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factor in cancers depending on the tissue. On the one
hand, TFF1 acts as a gastric tumor suppressor gene.
TFF1-KO mice therefore develop antro-pyloric adeno-
mas and carcinomas (Lefebvre et al., 1996; Karam et al.,
2008). Accordingly, TFF1 expression is reduced in
human gastric carcinomas due to TFF1 gene alterations
(Ribieras et al., 1998; Katoh, 2003; Shi et al., 2006). On
the other hand, TFF1 is expressed in numerous other
normal epithelia. Thus, TFF1 messenger RNA and/or
protein have been shown to be focally expressed
by normal mammary ducts (Poulsom et al., 1997;
Wilson et al., 2006; Madsen et al., 2007; Vestergaard
et al., 2008), and TFF1 is a human milk component
(Vestergaard et al., 2008). However, in breast cancers, as
in various other cancers, TFF1 expression is not
downregulated as observed in gastric tumors, but
strongly induced (Ribieras et al., 1998; Regalo et al.,
2005), suggesting a possible function as an oncogene
(Perry et al., 2008).
This question is important as the usefulness of TFF1 as
a pharmacological treatment on gut inﬂammatory dis-
orders, notably following chemo- or radio-therapies, is
being investigated (Katoh, 2003; Kjellev, 2009). However,
a therapeutic potential for antagonizing TFF1 has been
recently proposed for breast cancer treatment (Perry et al.,
2008). Thus, TFF1 breast function needs to be clariﬁed, in
order to evaluate the beneﬁts and side effects of such
therapies for the whole individual.
In the TFF1-negative normal immortalized MCF10A
human breast cell line, TFF1 gain-of-function did not
modify anchorage-dependent or -independent cell pro-
liferation, indicating that TFF1 is unable to induce cell
cycle, or to confer oncogenic potential in normal
mammary cells. Consistently, our previous in vivo
studies showed no obvious structural or functional
mammary gland alterations, or tumors in transgenic
mice speciﬁcally expressing TFF1 in their mammary
glands (Tomasetto et al., 1989). Moreover, cell migra-
tion and invasion were dramatically increased in
MCF10A/TFF1 compared with MCF10A/CTL cells,
conﬁrming that TFF1 is a motogenic factor. Interest-
ingly, motogenic and invasive activities are required
during mammary gland morphogenesis (Andrew and
Ewald, 2010), suggesting that TFF1 might be involved
in mammary gland ontogenesis and/or remodeling.
However, as TFF1-KO mice did not exhibit obvious
mammary gland alterations (Lefebvre et al., 1996), this
function may be compensated by another protein(s).
Figure 7 Impact of TFF1 knockdown on MCF7 cell proliferation
and colony formation in soft agar. (a) Using the MTT method, no
differences (NS) were observed between MCF7/shScr, MCF7/
shTFF1#1 and MCF7/shTFF1#4 cell proliferation. (b) MCF7/
shTFF1#1 and MCF7/shTFF1#4 developed more colonies in soft
agar than MCF7/shScr cells (Po0.001 and Po0.01, respectively).
Histograms: mean±s.e. of triplicates.
Figure 8 Impact of TFF1 knockdown on MCF7 cell tumorigenicity in nude mice. (a) Tumor occurrence after subcutaneous injection
in nude mice of 2.5 10
5 cells in the presence of E2. Curves showed that MCF7/shTFF1#1 tumors appeared earlier, and that their
incidence was higher than for MCF7/shScr tumors. (b) TFF1 tumor immunohistochemistry showed that MCF7/shScr tumor cells
strongly expressed TFF1, whereas only a few MCF7/shTFF1#1 tumor cells were TFF1 positive (brown). Bars: 30 microns.
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malignancy, we used the TFF1-negative MDA-MB-231,
and TFF1-positive MCF7 and ZR75.1 cell lines. All
were TFF1-independent for their anchorage-dependent
proliferation, conﬁrming that TFF1 did not accelerate
cell cycle, in agreement with previous MCF7 data (Kida
et al., 1993). MDA-MB-231/TFF1 and MDA-MB-231/
CTL cells produced similar numbers of clones in soft
agar. Moreover, forced TFF1 expression in MCF7 cells
in the absence of E2 does not induce cell proliferation or
colony formation. In the presence of E2, both MCF7/
CTL and MCF7/TFF1 cells showed increased cell
proliferation and colony formation but at similar levels,
indicating that these effects are not due to TFF1 but to
other E2-regulated molecule(s). Moreover, forced TFF1
expression in MCF7 has no effect on tumor develop-
ment in nude mice in the presence or absence of E2.
Together, these results indicate that TFF1 has no
oncogenic properties in ER-negative or ER-positive
breast cancer cells. By contrast, MCF7/shTFF1#1 cells,
whose endogenous TFF1 levels were dramatically
reduced, exhibited higher clonal growth in soft agar
than MCF7/shScr control cells. Thus, TFF1 reduces the
in vitro oncogenicity of MCF7 cells. Accordingly, the
incidence of tumors from MCF7/shTFF1#1 xenografts
in nude mice was higher than from MCF7/shScr
xenografts, showing that TFF1 negatively regulates
tumor development in vivo. This result was conﬁrmed
by a second approach to test the oncogenic potential of
endogenous TFF1 in vivo. DMBA-induced tumorigen-
esis in TFF1-KO mice led to higher mammary gland
tumor incidence, both in number and size, compared
with wild-type mice. Moreover, similar protective effects
of TFF1 were observed in the ovary and the lung. Thus,
TFF1 might exert a common function during tumor
development/progression, regardless of organ. In con-
trast, a recent study reports that TFF1 enhances in vitro
and in vivo oncogenic capacity of mammary carcinoma
cells. These authors concluded that TFF1 is an
oncogene and that anti-TFF1 might represent a new
therapeutical approach for breast cancers (Amiry et al.,
2009). These discrepancies between our results might
result from differences in cell lines and experimental
procedures used (for example, siRNA versus shRNA,
E2 status of culture media, orthotopic versus ectopic
xenografts).
TFF1 favors MDA-MB-231, MCF7 and ZR75.1
migration and invasion, two generic TFF1 functions
shared by normal and malignant epithelial cell lines
(Prest et al., 2002; Thuwajit et al., 2007; Tosco et al.,
2010). As cellular invasion and migration participate in
invasive processes, these data might suggest that TFF1
favors tumor spreading and metastasis development.
However, the assumption of TFF1 as a metastatic
factor should be re-examined given the following
evidences. First, TFF1 exerts both migration/invasion
and tumor suppressor functions in the stomach. Second,
highly metastatic human breast cancer cell lines (for
example, SK-BR3, MDA-MB-231) do not express
TFF1, whereas low-invasive cells (for example, MCF7
and ZR75.1) do. Third, it has been reported that soluble
motogens may have an effect on the balance between
cancer cell motility and proliferation, and that cell
proliferation and migration are mutually exclusive
(Giese et al., 2003). Fourth, although TFF1 is a human
milk component (Vestergaard et al., 2008), epidemiolo-
gical studies report a protective effect of long-term
suckling against breast cancers (Press and Pharoah,
2010). Fifth, among published clinical studies, more
have indicated that patients with TFF1-positive primary
breast tumors have better outcome (Rio et al., 1987;
Foekens et al., 1990; Poulsom et al., 1997; Ribieras
et al., 1998; Crosier et al., 2001; Corte et al., 2006;
Lacroix, 2006; Surowiak et al., 2006; Scott et al., 2007;
Markicevic et al., 2008; Stotter and Walker, 2009), than
worse outcome (Crosier et al., 2001; Smid et al., 2006;
Tjensvoll et al., 2009).
Although TFF1 inducing factors vary depending on
the tissue and/or their malignant status, for example,
gastrin in the normal stomach (Khan et al., 2003) and
E2 in breast tumors (Ribieras et al., 1998), it might be
hypothesized that TFF1 always exerts the same func-
tion(s). In this context, we propose that TFF1 favors cell
differentiation. Indeed, TFF1 limits gut-cell prolifera-
tion and apoptosis, and favors cell differentiation
(Tomasetto and Rio, 2005; Karam et al., 2008). More-
over, differentiation and motility are concomitant events
of normal gastro-intestinal epithelial cells. For example,
Table 1 Comparison of DMBA-induced tumors in wild-type and TFF1-KO mice
Organs Tumor incidence Size
a Number per mouse
Wild type TFF1-KO Wild type TFF1-KO Wild type TFF1-KO
Mammary gland 2/12 (17%) 5/10 (50%) 1.13 5** 2 1.5
Ovary 6/12 (50%) 10/10 (100%)
b,** 1.82 3.75*** 1 1
Lung 9/12 (75%) 10/10 (100%) 0.45 0.55 1.4 3.5***
Liver 0/12 (0%) 0/10 (0%) — — — —
Abbreviations: DMBA, 7,12-dimethylbenz[a]anthracene; TFF1, trefoil factor 1.
Histological examination of mammary glands, ovary, lung and liver from TFF1-KO and wild-type littermate mice, 22 weeks after DMBA
intragastric gavages. Tumor incidence, size and/or number were higher in TFF1-KO than in wild-type mice. The liver never developed tumors.
aLargest diameter in mm.
bTwo mice died before the end of the experiment.
**Po0.01, ***Po0.001.
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differentiation are correlated with TFF1 overexpression
(Choi et al., 2009). TFF1 also favors airway (Hoffmann,
2007) and conjunctival (Buron et al., 2008) epithelium
differentiation. Finally, TFF1-expressing primary breast
tumors exhibit higher tumor differentiation compared
with those devoid of TFF1 (Rio et al., 1987; Foekens
et al., 1990; Ribieras et al., 1998; Corte et al., 2006;
Surowiak et al., 2006; Markicevic et al., 2008).
Collectively, these data indicate that TFF1 does not
act as an oncogene in the mammary gland, but,
conversely, exerts a beneﬁcial function during malignant
processes in breast cancers.
Materials and methods
Retroviral vectors
TFF1 gain-of-function: full-length human TFF1 complemen-
tary DNA was inserted in EcoRI-digested pQCXIP vector
(Clontech, Saint-quentin, France) (pQCXIP hTFF1); control,
empty pQCXIP vector (Figure 1a). TFF1 loss-of-function:
complementary oligonucleotides of hTFF1 target sequences
were cloned in XhoI/EcoRI-digested pLMP retroviral vector
(Dickins et al., 2005) (pLMP shTFF1); control vector: 50-CCA
GTCGCCATTATAATGCAA-30 scramble sequence (pLMP
shScr) (Figures 5a and b). Positive clones were sequenced.
Cell culture and viral infection
MCF10A, MDA-MB-231, MCF7 and ZR75.1 human mam-
mary cells were grown in appropriate media (American Type
Culture Collection, Rockville, MD, USA). Retroviruses were
generated by co-transfection of pLMP or pQCXIP vector with
pCL-Ampho vector (Imgenex, San Diego, CA, USA) into
BOSC23 retroviral packaging cell line (Fugene 6 Reagent,
Roche, Mannheim, Germany). Viral particles were collected
48h after transfection. After retroviral infection (10mg/ml
polybrene, 20mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethane-
sulfonic acid), selected cells (0.5mg/ml puromycin) were pooled
for further use. Medium devoid of E2: charcoal dextran-
treated fetal calf serum, phenol red-free (E2-like molecule);
medium plus E2: oestradiol 10nM.
Western blot
For cell extract, after washing, cells were resuspended in lysis
buffer (50 mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1%
Triton X-100, 1  protease inhibitor cocktail). After three
freeze/thaw cycles, lysates were centrifuged and supernatants
mixed with SDS buffer. On 10–20% gradient SDS–polyacryla-
mide gel electrophoresis, 20mgo fp r o t e i no r2 5 ml of medium
(1.4 M b-mercaptoethanol) was analyzed. After electrotransfer,
nitrocellulose membranes (Schleicher and Schuell, Dassel,
Germany) were blocked (phosphate-buffered saline, 5% non-
fat dry milk, 0.1% Tween 20). Anti-TFF1 (Rio et al., 1988)
(p28O2; 1:10000; Euromedex, Illkirch, France), anti-b-actin
(1:10000; Sigma-Aldrich, StLouis, MO, USA), anti-tubulin and
anti-cathepsin D (Cath-D) (Capony et al., 1989) (1:10000 and
1:2000, respectively; Santa-Cruz Biotechnology, Santa Cruz,
CA, USA) primary antibodies, peroxidase-conjugated secondary
antibody (1:10000) and chemiluminescent substrate were used.
Migration and invasion
The lower Transwell chamber (Costar, Dutscher, Brumath,
France) contained cell appropriate medium (10% fetal calf
serum, 2% bovine serum albumin as chemoattractants). Cells
in appropriate medium (0.2% bovine serum albumin) were
seeded onto membranes of the upper Transwell chamber
(6.5mm diameter, 8mm pores) coated (invasion) or not
(migration) with matrigel (30mg/cm
2); MCF10A (2.5 10
4
cells, 16h), MDA-MB-231 (4 10
4 cells, 24h), MCF7 (10
5
cells, MCF7/shTFF1#1 72h, MCF7/shTFF1#4 48h, MCF7/
TFF1 48h) or ZR75.1 (10
5 cells, 72h). For MCF7 and ZR75.1,
medium also contained epidermal growth factor (200ng/ml)
(Doll et al., 2005). After incubation, cells were ethanol-ﬁxed
and stained (crystal violet). Cells at the membrane upper face
were scraped and those on four ﬁelds of the lower face counted
using an inverted microscope.
Cell proliferation
Cells were seeded on six-well plates. MCF10A and MDA-MB-
231 (5 10
3 cells per well), MCF7 (2 10
4 cells per well) and
ZR75.1 (4 10
4 cells per well) were cultured 5 days (appro-
priate culture medium, 1% fetal calf serum). Cell number was
measured using MTT method at OD 570nm (Bossenmeyer-
Pourie et al., 2002).
Soft-agar growth
Basal gel consisted of 1% agar (Sigma, St Louis, MO, USA) in
appropriate medium, and upper gel consisted of 10
3 cells mixed
in 0.7% agar in appropriate cell medium. After 18-day culture,
stained colonies (crystal violet) were visualized (MacroFluo,
Leica Microsystems (Wetzlar, Germany); bright ﬁeld; camera
CoolSnap CF; Photometrics (Tucson, AZ, USA)). Colony
number was quantiﬁed (MetaMorph, Molecular Devices,
Sunnyvale, CA, USA).
Tumorigenesis in nude mice
TFF1 gain-of-function: 10
6 cells (50ml phosphate-buffered
saline 1 ) (MCF7/CTL, 7 mice per set; MCF7/TFF1, 8 mice
per set) were subcutaneously injected into the back of 8-week-
old BALB/c nu/nu female mice (Charles River Laboratories,
Wilmington, MA, USA) treated or not with E2 in drinking
water (1mg/ml; Sigma-Aldrich) (Mira et al., 2004). TFF1 loss-
of-function: similar experiments were performed using
2.5 10
5 (50ml phosphate-buffered saline 1 ) MCF7/
shTFF1#1 or MCF-7/shScr cells (E2 in drinking water) (12
mice per set). Mice were examined every 3 days for tumor
appearance. Tumor volume was calculated using the formula
volume¼p width
2 length/6. Animal experiments were con-
ducted in accordance with the National Institutes of Health’s
Guide for the Care and Use of Laboratory Animals.
DMBA-induced tumorigenesis in TFF1-KO mice
TFF1-KO and wild-type littermate 129/Svj 8-week-old females
(Lefebvre et al., 1996) were given weekly 500mg DMBA
(Sigma-Aldrich) (200ml corn oil) by intragastric gavage, for 6
consecutive weeks (Masson et al., 1998). Twenty-two weeks
after, animals were killed. Mammary glands ( 10 glands for
each mouse), ovaries, lungs and liver were collected and ﬁxed
in phosphate-buffered formalin (4%) and parafﬁn embedded.
Tumor number and size were evaluated on ﬁve sections taken
at the largest part of the surgical pieces.
Histological analysis and immunohistochemistry of tumors
Histological examination was performed on hematoxylin–
eosin-stained parafﬁn sections under light microscope. For
TFF1 immunohistochemistry, p28O2 anti-TFF1 monoclonal
antibody (1:200; Euromedex, Illkirch, France) and a perox-
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Oncogeneidase–antiperoxidase system (Dako, Glostrup, Denmark)
were used.
Quantitative and statistical analyses
At least three independent experiments were performed.
Statistical differences were evaluated using student0s t-test or
w
2-test, and P-values lower than 0.05 were considered as
signiﬁcant. *Po0.05; **Po0.01; ***Po0.001.
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